Endothelins and arterial hypertension;L'ENDOTHELINE EST-ELLE IMPLIQUEE DANS L'HYPERTENSION?

Medecine/Sciences

Volumn 12, Issue 5, 1996, Pages 599-607

  Schiffrin, Ernesto L ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYCORTICOSTERONE ACETATE; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; VASOCONSTRICTOR AGENT;

ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ESSENTIAL HYPERTENSION; GENE AMPLIFICATION; HUMAN; NONHUMAN; RAT; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR ENDOTHELIUM;

ANIMALIA;

EID: 0029931452     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/789     Document Type: Review

References (56)

1. D'Orléans-Juste P, Gratton JP, Leduc R, Bkaily G, Claing A. L'endothéline: pharmacologie cavdiovasculaire et considérations physiopathologiques. médecine/sciences 1996; 12.
2. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5.
3. Lotersztajn S. Les endothélines. médecine/sciences 1993; 9: 1084-93.
4. Simonson MS, Dunn MJ. Endothelin Peptides and the Kidney. Annu Rev Physiol 1993; 55: 249-65.
5. Naruse M, Naruse K, Demura H. Recent advances in endothelin research on cardiovascular and endocrine systems. Endocrine J 1994; 41: 491-507.
6. Koseki C, Imai M, Hirata Y, Yanagisawa M, Masaki T. Autoradiographic distribution of binding sites for endothelin: a neuropeptide? Am J Physiol Regal Integr Comp Physiol 1989; 256: R858-66.
7. Schiffrin EL. Endothelin, potential role in hypertension and vascular hypertrophy. Hypertension 1995; 25: 1135-43.
8. Kohno M, Murakawa KI, Horio T, Yokokawa K, Yasunari K, Fukui T, Takeda T. Plasma immunoreactive endothelin-1 in experimental malignant hypertension. Hypertension 1991; 18: 93-100.
9. Yokokawa K, Tahara H, Kohno M, Murakawa KI, Yasunari K, Nakagawa K, Hamada T, Otani S, Yanagisawa M, Takeda T. Hypertension associated with endothelin-secreting malignant hemangioendothelioma. Ann Intern Med 1991; 114: 213-5.
10. Neild GH. Endothelin plasma levels in hypertension patients with vascular disease. J Hypertens 1994; 12: S17-20.
11. Oishi S, Sasaki M, Sato T. Elevated immunoreactive endothelin levels in patients with pheochromocytoma. Am J Hypertens 1994; 7: 717-22.
12. Edwards BS, Hunt SA, Fowler MB, Valantine HA, Anderson LM, Lerman A. Effect of cyclosporine on plasma endothelin levels in humans after cardiac transplantation. Am J Cardiol 1991; 9:782-4.
13. Carlini R, Obialo CI, Rothstein M. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens 1993; 6: 103-7.
14. Dohi Y, Lüscher TF. Endothelin in hypertensive resistance arteries: intraluminal and extraluminal dysfunction. Hypotension 1991; 18: 543-9.
15. Deng LY, Schiffrin EL. Effecis of endothelin-1 and vasopressin on resistance arteries of spontaneously hypertensive rats. Am J Hypertens 1992; 5: 817-22.
16. Nguyen PV, Yang X-P, Li G, Deng LY, Flückiger J-P, Schiffrin EL. Contractile responses and signal transduction of endothelin-1 in aorta and mesenteric vasculature of adult spontaneously hypertensive rats. Can J Physiol Pharmacol 1993; 71: 473-83.
17. 2+ responses to angiotensin II but not to endothelin-1. J Hypertens 1994; 12: 663-73.
18. Thorin-Trescases N, Hamilton CA, Jardine E, Jeid JL. Signal transduction mechanisms of the vasoconstriction in hypertension. Eur J Pharmacol 1994; 268: 199-207.
19. Küng CF, Lüscher TF. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension 1995; 25: 194-200.
20. Pasanisi F, Hamilton CA, Wadsworth R, Pryce C, Nixon G, Reil JL. Phosphoinositide metabolism and aging in aorta from SHR and WKY rats: effects of endothelin-1 and noradrenaline. Clin Exp Hypertens 1994; 16: 119-33.
21. Nguyen PV, Parent A, Deng LY, Flückiger JP, Thibault G, Schiffrin EL. Endothelin vascular receptors and responses in DOCA-salt hypertensive rats. Hypertension 1992; 19 (suppl II): 98-104.
22. Deng LY, Schiffrin EL. Effects of endothelin on resistance arteries of DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 1992; 262: H1782-87.
23. Schiffrin EL, Deng LY, Larochelle P. Morphology of resistance arteries and comparison of effects of vasoconstrictors in mild essential hypertensive patients. Clin Invest Med 1993; 16: 177-86.
24. Deng LY, Schiffrin EL. Effect of antihypertensive treatment on response to endothelin of resistance arteries of hypertensive rats. J Cardiovasc Pharmacol 1993; 21: 725-31.
25. Dohi Y, Criscione L, Pfeiffer K, Lüscher TF. Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension: studies in perfused mesenteric resistance arteries. J Cardiovasc Pharmacol 1994; 24: 372-9.
26. Corvol P, Alhenc-Gélas F, Soubrier F. L'endothélium, site de production et de métabolisme des peptides vaso-actifs. médecine/sciences 1993; 9: 1050-61.
27. B receptors mediate contraction to endothelin-1 in renal artery of aging SHR. Hypertension 1995; 25: 501-6.
28. Schiffrin EL, Deng LY, Larochelle P. Effects of a beta blocker or converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 1994; 23: 83-91.
29. Haynes WG, Hand MF, Johnstone HA, Padfield PL, Webb DJ. Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1. J Clin Invest 1994; 94: 1359-64.
30. Larivière R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993; 21: 294-300.
31. Larivière R, Day R, Schiffrin EL. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1993; 21: 916-20.
32. Day R, Larivière R, Schiffrin EL. In situ hybridization shows increased endothelin-1 mRNA levels in endothelial cells of blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Amer J Hypertens 1995; 8: 294-300.
33. Larivière R, Deng LY, Day R, Sventek P, Thibault G, Schiffrin EL. Increased endothelin-1 gene expression in the endothelium of coronary arteries and endocardium of DOCA-salt hypertensive rats. J Mol Cell Cardiol 1995; 27: 2123-31.
34. Larivière R, Sventek P, Schiffrin EL. Expression of endothelin-1 gene in blood vessels of spontaneously hypertensive rats. Life Sci 1995; 56: 1889-96.
35. Schiffrin EL, Larivière R, Li JS, Sventek P, Touyz RM. Deoxycorticosterone acetate plus salt induce overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension 1995; 25: 769-73.
36. Alberts GF, Peifley KA, Johns A, Kleha JF, Winkles JA. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem 1994; 269: 10112-8.
37. Hishikawa K, Nakaki T, Marumo T, Suzuki H, Kato R, Saruta T. Pressure enhances endothelin-1 release from cultured human endothelial cells. Hypertension 1995; 25: 449-52.
38. Hasegawa K, Fujiwara H, Doyama K, Inada T, Ohtani S, Fujiwara T, Hosoda K, Nakao K, Sasayama S. Endothelin-1-selective receptor in the arterial intima of patients with hypertension. Hypertension 1994; 23: 288-93
39. Zeiher AM, Ihling C, Pistorius K, Schächinger V, Schaefer HE. Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes. Lancet 1994; 344: 1405-6.
40. Douglas SA, Louden C, Vickery-Clark LM, Storer BL, Hart T, Feuerstein GZ, Elliott JD, Ohlstein EH. A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB20970. Circ Res 1994 ; 75: 190-7.
41. McMahon EG, Palomo MA, Brown MA, Bertenshaw ST, Carter JS. Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype A antagonist) on blood pressure in hypertensive rats. Am J Hypertens 1993; 6: 667-73.
42. A) receptor antagonist in conscious rats. J Cardiovasc Pharmacol 1992; 20: 940-8.
43. Nishikibe M, Tsuchida S, Okada M, Fukuroda T, Shimamoto K, Yano M, Ishikawa K, Ikemoto F. Antihypertensive effect of newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci 1993; 52: 717-24.
44. Clozel M, Breu V, Burri K, Cassal J-M, Fischli W, Gray GA, Hirth G, Löffler, Müller M, Neidhart W, Ramuz H. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993; 365: 759-61.
45. Clozel M, Clozel JP, Hess P. Endothelin receptor antagonism: a new therapeutic approach in experimental hypertension (abstr). Circulation 1993; 88 (suppl): I-316.
46. Li J-S, Larivière R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in DOCA-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994; 24: 183-8.
47. Li J-S, Schiffrin EL: Effect of chronic treatment with an endothelin receptor antagonist in adult spontaneously hypertensive rats. Hypertension 1995; 25: 532-5.
48. Li J-S, Schiffrin EL. Chronic endothelin receptor antagonist treatment of young spontaneously hypertensive rats. J Hypertension 1995; 13: 647-52.
49. B endothelin receptor antagonist, in DOCA-salt spontaneously hypertensive rats. Br J Pharmacol 1995; 115: 1377-81.
50. Li J-S, Schürch W, Schiffrin EL. Renal and vascular effects of chronic endothelin receptor antagonism in malignant hypertensive rats. Am J Hypertens 1996 (sous presse).
51. Deng LY, Day R, Schiffrin EL. Localization of sites of enhanced expression of endothelin-1 in the kidney of DOCA-salt hypertensive rats. J Am Soc Nephrol 1996 (sous presse).
52. Bird JL, Moreland S, Waldron TL, Powell JR. Antihypertensive effects of a novel endothelin-1 receptor antagonist in rats. Hypertension 1995; 25: 1191-5.
53. A receptor antagonist, in spontaneously hypertensive rats treated with DOCA-salt. Eur J Pharmacol 1994; 259: 339-42.
54. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994; 344: 852-4
55. Wenzel RR, Noll G, Luscher TF. Endothelin receptor antagonists inhibit endothelin in human skin microcirculation. Hypertension 1994; 23: 581-6.
56. Kurihara Y, Kurihara H, Suzuki H, et al (17 auteurs). Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994; 368: 703-10.